FIPI hydrochloride hydrate
SIGMA/F5807 - ≥98% (HPLC), powder
Synonym: 4-
CAS Number: 2329374-20-9
Empirical Formula (Hill Notation): C23H24FN5O2·HCl · xH2O
Molecular Weight: 457.93 (anhydrous basis)
MDL Number: MFCD12912411
Linear Formula: C23H24FN5O2·HCl · xH2O
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | off-white |
| form | powder |
| InChI | 1S/C23H24FN5O2.ClH.H2O/c2 |
| InChI key | ZORDQKCXPCXYKL-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | O.Cl.Fc1ccc2[nH]c(cc2c1)C |
| solubility | DMSO: >20 mg/mL |
| storage condition | desiccated |
| storage temp. | 2-8°C |
| Application: | FIPI (4-Fluoro-N-(2-(4-(5-fluo |
| Biochem/physiol Actions: | FIPI is a potent phospholipase D (PLD) inhibitor effective at sub-nM levels. Phospholipase D (PLD) and the lipid second messenger phosphatidic acid (PA) generated by PLD are implicated in many cell biological processes including Ras activation, cell spreading, stress fiber formation, chemotaxis, and membrane vesicle trafficking. FIPI inhibits both PLD1 and PLD2, rapidly blocking in vivo PA production. FIPI inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis, suggesting potential as a therapeutic for autoimmune diseases and cancer metastasis. |
| Biochem/physiol Actions: | FIPI is a potent Phospholipase D (PLD) inhibitor. |
| Biochem/physiol Actions: | FIPI is a potent Phospholipase D (PLD) inhibitor. The signaling enzyme Phospholipase D (PLD) and the lipid second messenger phosphatidic acid (PA) generated by PLD are implicated in many cell biological processes including Ras activation, cell spreading, stress fiber formation, chemotaxis, and membrane vesicle trafficking. FIPI is a potent in vivo inhibitor of both PLD1 and PLD2, setting the stage for a new era of exploration and validation of cell biological roles for mammalian PLD. It rapidly blocks in vivo PA production with sub-nM potency. FIPI inhibits PLD regulation of F-actin cytoskeleton reorganization, cell spreading, and chemotaxis, indicating potential utility for it as a therapeutic for autoimmunity and cancer metastasis. It does not affect PLD subcellular localization, PIP2 availability, the actin stress fiber network in resting CHO cells, or selected signaling events proximal to PLD activation. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352204 |


